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Abstract: The combination of programmed cell death 1/programmed cell death 
ligand 1 blockade and thoracic radiotherapy has become the new standard of care in 
the treatment of locally advanced non-small-cell lung cancer. The information 
regarding the pulmonary safety of such therapy remains limited to mostly 
retrospective studies and case reports with a small portion of data from prospective 
clinical trials. By analyzing the underlying mechanisms of interactions between 
radiation and immunotherapy from preclinical data and summarizing safety data from 
relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous 
follow-up is warranted, to determine if the combination of such modalities is 
appropriate for patients without risking undue toxicity. 
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Introduction 
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) 
immune checkpoint inhibitors (ICIs) are currently one of the most investigated 
immunotherapies. This blockade has proven its efficacy across various types of tumor 
including melanoma, Hodgkin`s lymphoma, head and neck cancer, and non-small-cell 
lung cancer (NSCLC)1,2. Objective tumor responses are observed in approximately 
40% of PD-L1-positive advanced NSCLC patients, accompanied by significantly 
increased progression-free survival (PFS) and overall survival (OS) 3-6. This clinical 
effect is derived from anti-PD-1/PD-L1 therapy enhancing the antitumor immune 
response7. Radiotherapy facilitates the initial antigen-specific immune responses by 
inducing inflammatory death of tumor cells, whereby fragmented tumor cells release 
previously obscured tumor-associated antigens and immune-stimulatory molecules 
which then trigger an immunogenic response which may elicit an in-situ tumor 
vaccination effect and abscopal effect8.  
 
Combining radiotherapy with immunotherapy has increasingly become of interest. 
Multiple preclinical studies demonstrated that thoracic radiotherapy (TRT) can 
augment the efficacy of anti-PD-1/PD-L1 therapy by priming and recruiting more 
antitumor effector T cells9-11. Recent clinical trials for anti-PD-1/PD-L1 therapy have 
explored the combination of anti-PD-1/PD-L1 therapy with various cancer 
therapeutics, including radiotherapy. The combination of anti-PD-1/PD-L1 therapy 
with TRT in treating locally advanced or metastatic NSCLC has significantly 
improved PFS and OS when compared with monotherapy, which is demonstrated by 
the KEYNOTE-001 trial (NCT01295827) (median PFS: 6.3 months vs. 2.0 months; 
median OS: 11.6 months vs. 5.3 months) and the PACIFIC study (NCT02125461) 
(median PFS: 16.8 months vs. 5.6 months; median OS: not reached vs. 28.7 
months)12-14. However, with this increased efficacy may come potential increases in 
toxicity15,16. In this review, we will explore the potential toxicity and the underlying 
mechanisms. Considering the underlying interactions between the two modalities with 
the currently available evidence, we acknowledge and appreciate the significant 
efficacy and tremendous promise of the combination of TRT and anti-PD-1/PD-L1 
therapy, but have reservations about the view claiming no undue toxicity of this 
combination therapy17. 
 
Pulmonary toxicity in anti-PD-1/PD-L1 therapy 
Anti-PD-1/PD-L1 monoclonal antibodies (mAbs), is capable of effectively 
interdicting the immune inhibitory signals mediated by the interaction between PD-1 
and PD-L1, which recovers the priming of tumor-antigen-specific T cells and baseline 
immune response against tumor7 (Figure 1A).  
 
Figure 1. The schematic diagram of combination therapy-induced pulmonary toxicity. (A) PD-1/PD-L1 
axis inhibitors are capable of effectively recovering the baseline T-cell immune response against tumor. 
Inflammatory factors secreted by activated T cells are able to recruit more immunocytes that amplify 
the anti-tumor effects as well as the pulmonary toxicity. (B) Thoracic radiotherapy generates DNA 
damage to lung tissue, which contributes to the release of cytokines and chemokines that recruit and 
activate immunocytes and myo-fibroblasts. (C) The combination of radiotherapy and anti-PD-1/PD-L1 
monoclonal antibodies (mAbs) could incur more serious adverse effects relevant to DNA damage, 
redundant immunocytes infiltrating and inflammatory factors releasing, and collagen deposition. 
 
Unfortunately, PD-1/PD-L1 blockade can cause collateral damage to normal organs 
and tissues, termed immune-related adverse events (irAEs)18, i.e. toxicity mediated by 
antibodies, T cells, and cytokines attacking self-antigens. Anti-PD-1/PD-L1 
therapy-related pneumonitis, defined as the inflammation of lung parenchyma, is an 
indicator of potentially life-threatening irAEs and appears to occur more commonly in 
patients with lung cancer19, having resulted in pneumonitis-related deaths observed in 
several clinical trials18,20. Paradoxically, NSCLC patients who received nivolumab 
and developed irAEs had better OS and longer PFS as compared to those without 
irAE21. The pneumonitis has been reported to occur in 0-10% of the patients receiving 
anti-PD-1/PD-L1 monotherapy or combination therapy. Delaunay et al. unveiled the 
outcomes of a large-scale retrospective study wherein 1826 cancer patients were 
treated with ICIs including PD-1 inhibitors, and 3.5% of the patients developed 
interstitial lung diseases (ILDs)22. Fortunately, grade 3 or higher pulmonary adverse 
events are relatively uncommon in patients.  
 
The underlying etiology and mechanisms of pneumonitis associated with 
anti-PD-1/PD-L1 mAbs have not been completely determined. One of the potential 
risk factors for developing irAEs is due to pre-existing autoimmune diseases or 
subclinical autoimmune syndromes. The PD-1/PD-L1 signaling pathway is an 
evolutionarily conserved mechanism that maintains self-tolerance mainly through the 
inhibition of self-reactive T/B cell responses23. Autoimmune conditions can be 
exacerbated by lowering the threshold for immune activation through checkpoint 
inhibition24, resulting in significantly increased risk of irAEs without affecting the 
therapeutic effects25. Another possible mechanism for immune-related pulmonary 
toxicity is elicited against antigens shared by the tumor and irAE lesions. It has been 
suggested that pneumonitis observed in patients under PD-1 blockade may be related 
to the T cells that are similar to the tumor-infiltrating T cells. Moreover, involved T 
cell clones were also found in the peripheral blood26, which means any organ with 
alike antigens may be inflicted by the circulating antigen-specific T cells.  
 
Interestingly, anti-PD-1 mAbs have been associated with a slightly higher incidence 
of pneumonitis as compared to anti-PD-L1 mAbs (3.6% vs. 1.3%), especially 
regarding to the grade 3–4 pneumonitis (1.1% vs. 0.4%)20. A meta-analysis estimated 
that the incidence of any grade pneumonitis among NSCLC patients on anti-PD-1 
therapies is 4.1%18. One of the possible mechanisms for higher incidence of 
PD-1-induced pneumonitis lies in the prevention of interaction between PD-L2 and 
PD-1 by PD-1 blockade. The PD-L2 ligand mainly expresses on DCs, macrophages, 
Th2 cells and activated T cells. On one hand, Latchman et al. identified that both 
PD-1-PD-L2 and PD-1-PD-L1 signals inhibited the cytokine production and/or cell 
proliferation of CD4+ T cells by blocking cell cycle progression27. On the other hand, 
PD-1 blockade increases the binding of PD-L2 to repulsive guidance molecule b 
(RGMb) that expresses in various cancer lines, mouse splenic CD4+ and CD8+ T 
cells, pulmonary interstitial macrophages, and alveolar epithelial cells, thus leading to 
vigorous clonal expansion of lung resident T cells and subsequent pneumonitis in the 
absence of PD-1-mediated tolerance to self-antigens28. In addition, a recent study 
provides evidence of direct interactions between tumor stroma and T cells, showing 
that reciprocal expression of ligands FASL and PD-L2 was detected in 
cancer-associated fibroblasts that kill CD8+ T cell via the interaction of PD-L2 with 
PD-1 and FASL with FAS29. Therefore, the absence of interplay between PD-1 and 
PD-L2 not only promotes the cytokine production and expansion of self-reactive T 
cells, but also exempts them from being braked and eliminated, which may sharply 
enhance the anticancer effect as well as the side effects. While PD-L1 blockade could, 
to an extent, circumvent the restrictions above. This may partially explain the 
incidence disparity of pulmonary toxicity between PD-1 and PD-L1 blocking30.  
  
Anti-PD-1/PD-L1 therapy-related pneumonitis can manifest as shortness of breath, 
cough, fever, or chest pain19. Standard of care is guided by clinical symptoms, 
recommending that mild cases (grade 1–2) are managed with suspending therapy, and 
higher grade cases with oral or intravenous corticosteroids (grade 2–4), among which 
severe cases result in hospitalization for intravenous corticosteroids, the permanent 
cessation of ICIs, and other forms of immunosuppression such as infliximab31. 
 
 
 
Pulmonary toxicity in TRT 
Delivery of ionizing radiation to thoracic region in cancer patients, particularly in 
NSCLC patients, faces a major limitation known as the radiation-induced lung 
injuries (RILIs), which is thought to be caused by reactive oxygen species produced 
during the treatment course that leads to DNA damage and subsequent inflammatory 
responses32. Radiation pneumonitis, usually occurring 1–6 months after RT, and 
pulmonary fibrosis, developing gradually months to years later, are recognized as the 
acute and late phases in the development of RILI, respectively33. Symptoms relevant 
to RILI are often observed 1–6 months after RT, and may manifest as dyspnea, cough, 
pyrexia, and mild chest pain. On symptoms progressing, acute respiratory distress 
inflicted on patients can be life-threatening. RILI is commonly managed with 
glucocorticoids, supplemental oxygen, as well as antitussive medications if clinically 
indicated32.  
 
The primary and optimal strategy to prevent RILI is through rigorous radiation 
treatment planning to reduce the development of RILI. Treatment plans are generally 
designed to achieve the percent of total lung volume receiving 20 Gy (V20) ≤ 30-37% 
and mean lung dose of ≤ 20-21 Gy33. Still, RILI cannot be avoided completely even 
with high-precision TRT. Delineation of clinical target volume and planning target 
volume requires margins around the tumor in consideration of microscopic diseases, 
respiratory motion, and setup variability. These margins increase the exposure of 
benign tissues to high-dose radiation and stimulate an inflammatory and immune 
reaction34. 
 
More importantly, disease progression poses a more serious risk than adverse events 
in patients receiving concurrent chemoradiotherapy. Therefore, adequate therapeutic 
tumor dose coverage is paramount, and some benign lung tissue will receive TRT for 
treating lung cancer. Taking the clinical trial RTOG 0617 as an example, a 
randomized phase III trial of concurrent chemoradiotherapy comparing 74 vs. 60 Gy 
and the use of chemoradiation with or without the addition of cetuximab, reported that 
without cetuximab the rate of grade ≥ 3 acute pneumonitis was about 5% with 60 Gy 
and less than 1% with 74 Gy (P = .25), while grade ≥ 3 late pulmonary toxicities 
(pneumonitis and pulmonary fibrosis) was around 2% in both groups35. The secondary 
analysis of RTOG 0617 comparing intensity-modulated radiation therapy (IMRT) 
with three-dimensional conformal external beam radiation therapy (3D-CRT) found 
that IMRT was less likely to induce severe pneumonitis (grade 3 pneumonitis, 3.5% 
vs. 7.9%, P = .039) and improved quality of life36.  
 
Other factors also known to influence the risk of pneumonitis development include 
smoking history, preexisting pulmonary function, tumor size and location, heart 
irradiation dose, select cytokine and glycoprotein levels, the receipt of carboplatin 
plus paclitaxel chemotherapy in addition to V20, and advanced age33,37. Among them, 
biomarkers, like IL-1α, IL-6, IL-8, sICAM-1, KL-6, CYFRA 21-1, TGF-β1, IP-10, 
MCP-1 and TIMP-1, are implicated to correlate with higher-grade pulmonary 
toxicity33,38,39. As an example, TGF-β1, which is activated by RT, facilitates the 
development and persistence of tissue remodeling and fibrosis in response to 
irradiation (Figure 1B and 1C). Notably, the production of TGF-β1 by 
tumor-associated regulatory T cells also has an important role in preventing the 
development of autoimmunity, which suppresses effector T cells and stimulate the 
immunosuppressive function of myeloid-derived suppressor cells40,41. 
 
Pulmonary toxicity with combined radiation and immunotherapy in the 
pre-clinical and clinical settings 
 
Pre-clinical data 
So far, most studies combining ICIs and TRT have suggested an acceptable safety 
profile in the oligometastatic cancer setting17. However, this data lacks robust 
randomized data. We speculate that the pulmonary toxicity would be increased as 
compared to a single modality, since the therapies may induce pulmonary toxicity 
together and could compromise this otherwise promising combination therapy. Briefly, 
TRT generates oxidative damage to DNA and proteins in lung tissue, causing 
pulmonary injuries and contributing to the release of tumor antigens and 
inflammatory factors. After tumor-antigen uptake and processing, antigen-presenting 
cells migrate to lymphoid organs, and activate naïve T cells therein to become effector 
T cells. Activated T cells that are further unleashed by anti-PD-1/PD-L1 therapy not 
only maintain powerful killing effect that may impair normal self-tissues, but can also 
secrete high-level cytokines that recruit more, even redundant immunocytes into the 
local regions of the lung. While immunosuppression mechanisms that include 
myeloid-derived suppressor cells and regulatory T cells are compromised in this 
setting. Thus, the synergistic interaction of the two treatments sharply amplifies 
anti-tumor effects, which may also exacerbate the pulmonary toxicity9,34. All of these 
events could magnify serious adverse effects relevant to DNA damage, redundant 
immunocytes infiltrating and inflammatory factors release, as well as collagen 
deposition, which goes against the theory of immune normalization that emphasizes 
the importance of recovering the lost antitumor immunity rather than immune 
enhancement2. (Figure 1C). 
 
Multiple pre-clinical studies have contributed to uncovering the mechanisms 
underlying the synergistic effect. To name a few examples, tumor antigen-specific 
interferon-γ produced by effector T cells was substantially enhanced locally by PD-1 
blockade in the presence of RT41. Remaining to be one of the most important 
pro-inflammatory cytokines, interferon-γ overexpression is also associated with a 
number of auto-inflammatory and autoimmune diseases42, which is reminiscent of the 
possible mechanisms of irAEs induced by anti-PD-1/PD-L1 therapy that is mentioned 
above. More specifically, Deng et al. demonstrated that combination therapy with IR 
and PD-L1 blockade optimizes antitumor immunity through enhanced production of T 
cell-derived tumor necrosis factor (TNF)9. TNF-α has been implicated in the 
pathogenesis of RILI and the induction of TGF-β138. Further, the elevation of plasma 
TGF-β1 during radiation therapy predicts radiation-induced pulmonary toxicity, 
which have been demonstrated in our pre-clinical study43. Of note, we also suggested 
that concurrent anti-PD-1 therapy during TRT could augment pulmonary toxicity and 
the consequent mortality in the mouse model, where CD8+ T lymphocytes and 
macrophages with strong positivity for TGF-β1 may have played a key role during the 
pathological process11. Therefore, the upregulation of TNF and TGF-β1 may partially 
account for the pulmonary toxicity of the combination therapy. 
 
Lastly, a recent perspective by Eric D. and Joe Y. Chang proposed that irradiation of 
each lesion within multiple tissue beds would fully expose both mutual and exclusive 
tumor-associated antigens and increase the probability of systemic activation of 
antitumor immunity better than ICI monotherapy. However, they warned that the 
safety of multisite comprehensive irradiation has not been routinely analyzed, 
concerns regarding the toxicities of this approach still remain44.  
 
Clinical data 
Radiotherapy has been thought to be the ideal partner for ICIs44. Although there have 
been several prospective clinical trials combining RT and PD-1/PD-L1 inhibitors 
(Table 1) started in recent years, most of the trials are still ongoing. Only a small 
amount of evidence for this combination therapy is available for us at the present 
moment, and the safety profile appears to be acceptable (Table 2). 
 
Some case reports suggest caution for the diagnosis and management of the toxicity 
from the combination therapy. Louvel et al. reported two cases of six patients treated 
with concomitant therapy of PD-1/PD-L1 inhibitors and SBRT who developed a 
radiation pneumonitis45. Manapov et al. presented that 3 of 25 patients with advanced 
NSCLC received nivolumab that was initiated as second or third-line therapy several 
months after TRT developed grade 3 pneumonitis46. Yet it was uncertain whether 
these cases were just related to TRT or if the combination with ICIs played any 
enhancing role. More interestingly, Shibaki et al. presented two cases of 
nivolumab-induced radiation recall pneumonitis, where two patients with NSCLC 
received nivolumab treatment 2 years after 60 Gy of TRT developed pneumonitis. 
The area of nivolumab-induced pneumonitis was consistent with the radiation field in 
both patients47. Although the mechanism of recall pneumonitis is unknown, it seems 
presumable that nivolumab may have evoked an inflammatory reaction in the 
patients` previously irradiated fields. 
 
 
 
 
 
 
 
 
Registration 
Number 
Phases Tumor 
Stage 
Intervention / Treatment Arms 
NCT03446547 Ⅱ Ⅰ Durvalumab 1500 mg i.v. every fourth week following SBRTa. SBRT vs. SBRT + Durvalumab 
NCT03383302 Ⅰ/Ⅱ Ⅰ/Ⅱ A flat dose of 240 mg nivolumab infusion will begin after the final fraction 
of SBRT within 24 hours and subsequently be given every 2 weeks at a flat 
dose of 240 mg.  
SBRT + Nivolumab (adjuvant) 
NCT02768558 Ⅲ Ⅲ Patients will receive 60 Gy of thoracic RT; Cisplatin and Etoposide 
followed by Nivolumab/Placebo 2 weeks. 
Placebo vs. CRTb + Nivolumab 
NCT03245177 Ⅰ Ⅲ, Ⅳ The first dose of pembrolizumab is administered 14 days prior to the 
initiation of radiotherapy (60-66 Gy in 2 Gy/f, over 40-45 days) and 
following radiotherapy every 3 weeks thereafter. 
RTc + Pembrolizumab (concurrent) 
NCT02434081 Ⅱ Ⅲ A/B Four doses of nivolumab 360 mg concurrently with standard 
chemo-radiotherapy, followed by 480mg from start of nivolumab treatment. 
CRT + Nivolumab        
(concurrent & adjuvant) 
NCT03368222 Ⅰ Ⅲ B/ Ⅳ Part A-DOSE LEVEL 1: 200 mg pembrolizumab in week 1 (then 3 weekly) 
+ SBRT dosed at 30 Gy in 3 fractions in week 3. DOSE LEVEL 2: 200 mg 
pembrolizumab in week 1 (then 3 weekly) + SBRT at 54Gy/ 3f in week 3. 
Part B-12 patients receive 200 mg of pembrolizumab in week 1 (then 3 
weekly) + SBRT in week 3. 
RT + Pembrolizumab      
(concurrent & adjuvant) 
NCT02621398 Ⅰ Ⅱ–Ⅲ B Beginning 2–6 weeks after, 2 weeks before the end, or at the start of 
chemotherapy and radiation therapy, patients also receive pembrolizumab. 
CRT + Pembrolizumab (concurrent) 
NCT03307759 Ⅰ IV SABRd followed by pembrolizumab vs. Pembrolizumab followed by SABR 
after cycle 1 
SABR + Pembrolizumab    
(concurrent vs. adjuvant) 
NCT03158883 Ⅰ IV Avelumab: 10 mg/kg administered q2w.  
SABR: 50 Gy/5f on every 2 day  
SABR + Avelumab         
(concurrent & adjuvant) 
NCT03044626 Ⅱ Ⅳ Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. 
A metastatic site will be treated with a radiation dose at 20 Gy/5f during a 
two-week time interval. 
SBRT + Nivolumab        
(concurrent & adjuvant) 
NCT02407171 Ⅰ/Ⅱ IV The starting radiotherapy dose will be 30 Gy/5f and a dose escalation cohort 
(30Gy/ 3f). MK-3475: 200mg every 2 weeks 
SBRT + MK-3475          
(concurrent & adjuvant) 
NCT02400814 Ⅰ IV Concurrent: MPDL3280A on day 1; SABR begins on day 1 of course 1. 
Induction: MPDL3280A on day 1; SABR begins on day 1 of course 3. 
Sequential: SABR begins on day 1 of course 1. After completion of SABR, 
MPDL3280A IV begins. 
SABR + MPDL3280A      
(concurrent vs. adjuvant vs. 
sequential)  
NCT03313804 Ⅱ IV Immune checkpoint inhibitor PLUS SBRT SBRT + Nivolumab/Pembrolizumab 
/Atezolizumab 
NCT03212469 Ⅰ/Ⅱ IV Durvalumab q4w+ Tremelimumab q4w for up to 4 doses in conjunction 
with SBRT, then Durvalumab q4w alone for up to 9 additional doses. 
SBRT + Durvalumab + 
Tremelimumab 
NCT02444741 I/II IV PhaseⅠ: Starting dose of Pembrolizumab 100 mg by vein on Day 1 of each 
3-week cycle. 
PhaseⅡ: Starting dose of Pembrolizumab at the maximum tolerated dose 
from Phase I. SBRT delivered at 50 Gy in 4 daily fractions. Wide-field 
radiation therapy delivered at 45 Gy in 15 daily fractions. 
Pembrolizumab + SBRT/ WFRT vs. 
Pembrolizumab 
 
Table 1. Ongoing clinical trials that are testing the effects of combinatorial therapy of programmed cell 
death 1 (PD-1) /programmed cell death ligand 1 (PD-L1) inhibition and RT in the treatment of lung 
cancer. SBRTa: Stereotactic body radiation therapy; CRTb: Chemoradiotherapy; 
RTc: Conventional fractionated radiotherapy; SABRd: Stereotactic ablative radiotherapy. 
 
Study Study Type Tumor and Stage Intervention / Treatment Incidences of Pulmonary Toxicities 
Nishino M, et al.18 Meta-analysis.  
(Including phase I–III) 
Only NSCLCa included 
in this table 
PD-1b inhibitor monotherapy All-grade pneumonitis: 4.1% 
Khunger M, et al.20 Meta-analysis.  
(Including phase I–Ⅳ) 
NSCLC PD-1/PD-L1c inhibitor 
monotherapy 
All-grade pneumonitis: 3.6% in PD-1 
inhibitors, 1.3% in PD-L1 inhibitors 
Bradley JD, et al. 35 Prospective study 
(Phase III) 
Stage IIIA/IIIB NSCLC TRTd: 60 Gy vs. 74 Gy        
(without chemotherapy) 
All-grade acute pneumonitis: about 
9% in the 60 Gy arm, about 11% in 
the 74 Gy arm 
All-grade late pneumonitis: about 
12% in the 60 Gy arm, 7% in the 74 
Gy arm 
All-grade late pulmonary fibrosis: 
10% in the 60 Gy arm, 6% in the 74 
Gy arm 
Curran WJ, et al. 48 Prospective study 
(Phase III) 
Stage II, IIIA, or IIIB Chemotherapy + TRT: 
Arm 1: sequential (63 Gy)   
Arm 2: concurrent (63 Gy)   
Arm 3: concurrent (69.6 Gy) 
Grade ≥ 3 acute pulmonary toxicities: 
9% in arm 1, 3-4% in arm 2 and 3; 
Grade ≥ 3 late pulmonary toxicities: 
14% in arm 1, 13% in arm 2 and 17% 
in arm 3; 
 
Antonia SJ, et al.12 Prospective study 
(Phase III) 
Locally advanced NSCC CRTe + Durvalumab All-grade pneumonitis: 33.9% 
All-grade pneumonia: 13.1% 
Grade ≥ 3 pneumonitis: 3.4% 
Grade ≥ 3 pneumonia: 4.4% 
Shaverdian, N, et al.13 Post hoc analysis Advanced NSCC TRT + Pembrolizumab  All-grade pulmonary toxicities: 13% 
Peters S, et al.49 Prospective study 
(Phase II) 
Stage III NSCLC CRT + Nivolumab All-grade pneumonitis: 35.4% 
All-grade Pulmonary fibrosis: 1.7% 
Durm, G. A., et al.50 Prospective study 
(Phase II) 
Stage III NSCLC CRT + Pembrolizumab Grade ≥ 2 pneumonitis: 17.2% 
Grade ≥ 3 pneumonitis: 6.5% 
Botticella, A., et al.51 Retrospective study NSCLC TRT+ICIs
f All-grade pneumonitis: 16.7% 
Grade ≥ 3 pneumonitis: 11.1% 
Reibnitz, D, et al.52 Retrospective study Advanced lung cancer   
or other tumors with lung 
metastases 
TRT + anti-PD-1/PD-L1 (78%) / 
anti-CTLA-4 (15%) / 
anti-PD-1/PD-L1 and  
anti-CTLA-4 (6%) 
Grade ≥ 2 pneumonitis: 6.3% 
Grade ≥ 2 pneumonia: 17.7% 
Hwang WL, et al.17 Retrospective study Metastatic NSCLC (95%) 
and SCLCg (5%) 
TRT + anti-PD-1/PD-L1 All-grade pneumonitis: 8.2% 
Voong KR, et al.53  Retrospective study NSCLC TRT + anti-PD-1/PD-L1 All-grade pneumonitis: 25% 
Shibaki R, et al.47 Case report NSCLC TRT + Nivolumab Two patients with nivolumab-induced 
radiation recall pneumonitis 
Manapov F, et al.46 Case report Advanced NSCLC TRT + Nivolumab Three patients with grade 3 
pneumonitis 
Louvel G, et al.45 Case report Patient 1: metastatic 
melanoma 
Patient 2: metastatic 
colon cancer 
Patient 1: concomitant 
pembrolizumab + TRT 
Patient 2: concomitant 
atezolizumab + TRT  
Two patients with radiation 
pneumonitis 
Table 2. Important studies reporting pulmonary toxicity of monotherapy and of the combination of 
thoracic radiotherapy (TRT) and programmed cell death 1/programmed cell death ligand 1 inhibition. 
Pneumonitis and pneumonia are both included in the pulmonary toxicity analysis, because differential 
diagnosis between pneumonia and pneumonitis relating to immunotherapy or radiotherapy may be 
clinically challenging. NSCLCa: Non-small cell lung cancer; PD-1b: programmed cell death 1; PD-L1c: 
programmed cell death ligand 1; TRTd: Thoracic radiotherapy; CRTe: Chemoradiotherapy; ICIsf: 
immune checkpoint inhibitors; SCLCg: Small cell lung cancer 
 
As for retrospective studies, most of them appear to claim that combining PD-1 
inhibitors and RT does not result in increased toxicity. Bang et al. retrospectively 
reviewed patients with metastatic NSCLC, melanoma and renal cell cancer, who 
received CTLA-4 or PD-1 inhibitors and palliative radiotherapy. No relationship 
between radiation fields and specific irAEs was identified. For instance, 2 in 34 
patients (6%) who received TRT and 1 of 79 patients (1%) who did not developed 
pneumonitis (P = .16)54. A retrospective cohort study by Hwang et al. included 
patients with metastatic lung cancer treated with anti-PD-1/PD-L1 therapy. Incidences 
of all-grade pneumonitis (8.2% vs. 5.5%) as well as pneumonitis grade ≥ 2 (4.1% vs. 
3.3%) were not significantly different between the TRT and non-TRT cohorts17. 
Naidoo et al. analyzed patients who received anti-PD-1/PD-L1 mAbs monotherapy or 
in combination with anti-CTLA-4 mAb, and revealed that most of the patients that 
developed pneumonitis had not received prior TRT (27 of 43 [63%])55. 
 
In stark contrast, one study group from Johns Hopkins University retrospectively 
investigated the role of TRT and the development of immune-related pneumonitis in 
184 NSCLC patients who received anti-PD-1/PD-L1 therapy. Anti-PD-1/PD-L1 
monotherapy was received in 74% and in combination with other systemic therapy in 
26% of the patients. TRT was performed 96 patients (52%). A total of 38 (21%) 
patients developed pneumonitis, which was more common than that were reported in 
other clinical trials. Moreover, there was a strong trend towards increased 
immune-related pneumonitis in patients who underwent TRT compared with those 
who received other RT (25% vs. 9%, P = 0.08)53. Together with another retrospective 
study by the same study group, the overall incidence of checkpoint inhibitor 
pneumonitis is found to be significantly higher than that was reported in other clinical 
studies56. The retrospective study by Botticella et al. also supported that NSCLC 
patients treated with ICIs and previous curative-intent TRT may be at higher 
pulmonary risk, where pneumonitis of grade ≥ 3 occurred in 16.7% of the patients on 
combination therapy and in 2.4% of the patients on ICI monotherapy (P < 0.001)51. 
Possible reasons include increased awareness and pharmacovigilance with irAEs in 
recent years.  
 
However, limitations of the above retrospective analyses are inherent to the nature of 
such studies, including incomplete information, lengthy median time between TRT 
and ICI treatment, and combined analysis of different doses and purposes. Therefore, 
we should be careful when extrapolating this information. 
 
In the post hoc analysis of the phase I KEYNOTE-001 trial (NCT01295827), all 
included patients with advanced NSCLC received pembrolizumab and were coded for 
having received previous RT (extracranial or thoracic) or not. Significantly prolonged 
PFS and OS were observed in patients with advanced NSCLC who had received any 
RT before receiving pembrolizumab than that in patients who did not have. Of note, 
comparing the 24 patients who received previous TRT and the 73 patients who did not, 
there was a statistical increase in treatment-related pulmonary toxicities (13% vs. 1%, 
P = .046), and a borderline significance was found in the incidence of all pulmonary 
toxicities (63% vs. 40%, P = .052), including dyspnea, cough, pneumonitis, and 
respiratory failure. Although no frequency difference was found in the grade ≥ 3 
pulmonary toxicity in both treatment-related pulmonary toxicities and all pulmonary 
toxicities, RT was implemented at a median of 11.5 months before pembrolizumab 
treatment13. Exposing NSCLC patients to TRT can induce RILI that develop over 
weeks to months or years33. In this study, since TRT was performed several months 
(median 9.5 months, range 1.0-106.0) prior to ICIs, patients with RILI, especially 
with severe pneumonitis (grade ≥ 3), may well be excluded from the subsequent ICIs 
therapy as per the exclusion criteria of most clinical trials. That is, those who received 
combination therapy were pulmonary function-competent and more likely to 
withstand the subsequent immunotherapy. In conclusion, KEYNOTE-001 trial can, to 
some extent, support our perspective that combination therapy augments pulmonary 
toxicities. 
The PACIFIC study (NCT02125461), a prospective, randomized, double-blind, 
placebo-controlled phase III study enrolled patients with locally advanced NSCLC 
that had received platinum-based chemotherapy concurrently with definitive radiation 
therapy (54–66 Gy). Durvalumab, a PD-L1 inhibitor, was administered 1 to 42 days 
after completion of chemoradiotherapy in the experimental arm, while placebo was 
administered in the control arm. Pneumonitis of any grade occurred in 33.9% and 
24.8% of patients in the durvalumab arm and placebo arm, respectively; grade 3 and 4 
occurred in 3.4% and 2.6%, respectively12. P-values for the pulmonary safety data 
were not reported. The incidence of grade ≥ 3 pneumonitis in the placebo group was 
comparable to that in RTOG 9410 (3.4% vs. 1–5%)35. However, pneumonitis of any 
grade was more common in both treatment of PACIFIC than that in ATLANTIC 
study, a durvalumab monotherapy study (33.9% & 24.8% vs. ≤ 3%)57. This variability 
may be attributed to the requirement for prior TRT in PACIFIC, which could have 
predisposed patients to pulmonary adverse events, a hint for the role of TRT in 
increasing pulmonary side effects58. Symptoms such as cough (35.4% vs. 25.2%), 
dyspnea (22.3% vs. 23.9%) and pyrexia (14.7% vs. 9.0%), which are possibly relevant 
to RILI and have been included in KEYNOTE-001 trial and other studies19, were not 
included in the pulmonary toxicity analysis of this study. Additionally, differentiating 
between pulmonary infection (pneumonia in both arms: 13.1% vs. 7.7%) and 
pneumonitis relating to immunotherapy or radiotherapy may be clinically 
challenging59,60. Hence, we conjecture that the authentic incidence of pulmonary 
toxicity has been underrated because of the exclusion of other respiratory symptoms 
and pneumonia from pulmonary toxicity analysis.  
 
Another multicenter single-arm phase II study spearheaded by Indiana University 
adopting the same treatment mode as the PACIFIC study reported the incidence of 
grade ≥ 3 pneumonitis at 6.5%, which is the double of the PACIFIC study50. However, 
only 43.5% of patients completed the one-year adjuvant immunotherapy and 19.6% 
failed due to adverse events, suggesting the incomplete information of pneumonitis 
incidence on combination therapy. Of note, 75% cases of grade ≥2 pneumonitis 
occurred within the first 12 weeks after pembrolizumab treatment50. Similarly, with 
TRT and immunotherapy being prescribed sequentially rather than concurrently, the 
report of the second primary endpoint for PACIFIC study revealed that time < 14 days 
from prior RT to randomization witnessed quite different proportions of any-grade 
pneumonitis (39.2% vs. 16.7%, without the P-value reported) in the durvalumab arm 
and placebo arm61.which is reminiscent of concurrent combination therapy that is 
more likely to prime a stronger immune response44 as well as worsen the pulmonary 
toxicity in the light of published preclinical evidence from concurrent irradiation and 
PD-1 blockade in increasing cardiac toxicity62,63. The safety data from NICOLAS 
(NCT02434081) study, to some extent, corroborates our speculation. This is a 
single-arm study evaluating the safety of combining nivolumab with the first-line 
chemo-TRT (≥ 60 Gy) regimen in stage III NSCLC. Pneumonitis of any grade 
occurred in 32.7% of the evaluated 58 patients, with grade 1/2 and 3 making up 
22.4% and 10.3%, respectively. Pneumonitis of grade ≥ 3 is remarkably increased as 
compared to studies above, while the remaining respiratory disorders, including 
dyspnea (20.7%), cough (31.0%), pulmonary fibrosis (1.7%) and respiratory 
insufficiency (1.7%), are comparable to other studies49.  
 
Real-World Toxicities Higher Than in Trials 
 
Even if prospective clinical trials, such as the PACIFIC study, have offered more 
objective and reliable evidence as compared with retrospective studies, their results 
may still not reflect the real-world data. For instance, patients with history of 
interstitial lung disease (ILD) were routinely excluded from the clinical trials studying 
the combination of ICIs and TRT. In fact, the incidence of lung cancer is high in 
patients with idiopathic pulmonary fibrosis (25.2 cases per 1000 person-years), a 
specific form of ILD of unknown cause64. NSCLC patients who were treated with 
SBRT, the cumulative incidences of radiation pneumonitis worse than grade 2 (55.0% 
vs.13.3%, P < .001) and worse than grade 3 were significantly higher in ILD (+) 
group than those in ILD (−) group (10.0% vs. 1.5%; P = .02)65. Furthermore, referring 
to the instructions of anti-PD-1/PD-L1 mAbs, in the case of grade 2 or higher-grade 
immune-mediated pneumonitis or ILD, withholding immunotherapy is emphasized. 
Collectively, patients with ILD are more prone to pulmonary toxicities by TRT, ICIs, 
or more possibly by the combination therapy. The exclusion of this patient group 
could artificially reduce the incidence of combination therapy-related pneumonitis. 
Additionally, with the improvement of medical technology and our ability to diagnose 
irAEs, rates are increasing as observed at the population level56.  
 
Conclusion 
Since most irAEs are treatable, recognizing these events earlier on could improve 
quality of life of patients. Our purpose is to promote awareness amongst medical 
oncologists, radiation oncologists, pulmonologists, emergency physicians, and other 
medical providers to have a high index of suspicion of potential pulmonary toxicity 
from the combination of radiation therapy with immunotherapy in the setting of 
advanced NSCLC. Most of the available data suggests that combining radiation and 
immune checkpoint blockade are generally safe, but more data with longer and rigorous 
follow-up are needed. Whether such a treatment course is appropriate for patients 
without risking undue toxicity from co-administration is left unanswered at this time. 
The information presented above presents a potential trend towards increased 
incidence of immune-related, radiation pneumonitis in patients on combination 
therapy. Therefore, we are cautiously optimistic and recommend attention to 
monitoring for pneumonitis in patients with NSCLC during combination therapy, 
particularly with anti-PD-1/PD-L1 inhibitors. 
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